Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Waist-Hip Ratio
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
|
30867289 |
2019 |
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
|
30343511 |
2019 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
|
30343511 |
2019 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
EZH1/2 function mostly within canonical PRC2 and exhibit proliferation-dependent redundancy that shapes mutational signatures in cancer.
|
30867289 |
2019 |
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Notably, this combination also exhibited strong synergy in prostate cancer cells.<b>Conclusions:</b> Our results identify dual inhibition of EZH2 and EZH1 together with proteasome inhibition as a promising epigenetics-based therapy for PRC2-dependent cancers.<i>Clin Cancer Res; 23(16); 4817-30.©2017 AACR</i>.
|
28490465 |
2017 |
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
A solid cancer panel assay demonstrated that some cancer cell lines are sensitive to EZH1/2 dual inhibitor in vitro and in vivo.
|
28741798 |
2017 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Notably, this combination also exhibited strong synergy in prostate cancer cells.<b>Conclusions:</b> Our results identify dual inhibition of EZH2 and EZH1 together with proteasome inhibition as a promising epigenetics-based therapy for PRC2-dependent cancers.<i>Clin Cancer Res; 23(16); 4817-30.©2017 AACR</i>.
|
28490465 |
2017 |
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
A solid cancer panel assay demonstrated that some cancer cell lines are sensitive to EZH1/2 dual inhibitor in vitro and in vivo.
|
28741798 |
2017 |
Leukemia, Myelocytic, Acute
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
EZH1/2 expression and mutation were analysed in 200 patients with AML.
|
31794134 |
2020 |
Leukemia, Myelocytic, Acute
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our analysis implicated <i>BCL2</i> expression level as an important indicator of venetoclax responsiveness and provided a rationale for its targeting in specific leukemia subtypes and multiple myeloma, linked several polycomb group proteins that could be targeted by small molecules (SFMBT1, CBX7, and EZH1) with chronic lymphocytic leukemia, and supported <i>CDK6</i> as a disease-specific target in acute myeloid leukemia.
|
30940663 |
2019 |
Multiple Myeloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Polycomb repressive complex 2 (PRC2) components, EZH2 and its homolog EZH1, and PI3K/Akt signaling pathway are focal points as therapeutic targets for multiple myeloma.
|
31571328 |
2019 |
Multiple Myeloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our results show the role of EZH1/2 in the maintenance of myeloma stem cells and provide a preclinical rationale for therapeutic application of OR-S1, leading to significant advances in the treatment of MM.
|
30343511 |
2019 |
Leukemia, Myelocytic, Acute
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Genetic deletion of Ezh1/2 in a mouse AML model induced cell cycle progression of quiescent LSCs and differentiation to LSCs, eventually eradicating AML LSCs.
|
28951561 |
2018 |
Multiple Myeloma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here, we investigated the preclinical effects of UNC1999, a dual inhibitor of EZH2 and EZH1, in combination with proteasome inhibitors on multiple myeloma and prostate cancer.<b>Experimental Design:</b><i>In vitro</i> and <i>in vivo</i> efficacy of UNC1999 and the combination with proteasome inhibitors was evaluated in multiple myeloma cell lines, primary patient cells, and in a xenograft model.
|
28490465 |
2017 |
Lymphoma
|
0.020 |
Biomarker
|
group |
BEFREE |
Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas.
|
31747604 |
2019 |
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Two hotspots of EZH1 mutations were only found in RAS-negative follicular-patterned tumors.
|
29723601 |
2018 |
Thyroid Gland Follicular Adenoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
EZH1 mutations were detected in 3% of follicular adenoma and in 20% of Hürthle cell adenoma, and one minimally invasive Hürthle cell carcinoma.
|
29723601 |
2018 |
Lymphoma
|
0.020 |
Biomarker
|
group |
BEFREE |
A hematological cancer panel assay indicated that EZH1/2 dual inhibitor has efficacy against some lymphomas, multiple myeloma, and leukemia with fusion genes such as MLL-AF9, MLL-AF4, and AML1-ETO.
|
28741798 |
2017 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
|
28490465 |
2017 |
Thyroid Gland Follicular Adenoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas.
|
27500488 |
2016 |
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, the role of microRNA-765/EZH1 axis in the progression of BCa was assessed.
|
31396353 |
2019 |
leukemia
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia.
|
31699991 |
2019 |
Chronic Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our analysis implicated <i>BCL2</i> expression level as an important indicator of venetoclax responsiveness and provided a rationale for its targeting in specific leukemia subtypes and multiple myeloma, linked several polycomb group proteins that could be targeted by small molecules (SFMBT1, CBX7, and EZH1) with chronic lymphocytic leukemia, and supported <i>CDK6</i> as a disease-specific target in acute myeloid leukemia.
|
30940663 |
2019 |